The logo of the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups held at the Porte de Versailles Exhibition Center in Paris, France on June 15, 2022.
Benoît Tessier | Reuters
Two weeks ago, Monique Griffin received an alarming email.
French pharmaceutical company Sanofi told her that a delayed shipment of the drug she relies on to manage a rare muscle-wasting disease had disrupted supplies. The next infusion was discontinued. Griffin, 51, who uses a wheelchair due to Pompe disease, worries what will happen if the shortage is not resolved soon.
“The bottom line is you’re reintroducing the disease,” she says. “That’s scary.”
More than three months after first reports of problems with the supply of Pompe disease drugs, the confusion continues and more patients are learning their IVs have been cancelled. Sanofi said it had made progress in restoring supplies to patients in some countries, but added that transportation delays could disrupt infusions to some U.S. patients until the end of November.
For more articles like this, sign up for the CNBC Cures newsletter.
A Sanofi spokesperson said there were no issues with the quality of the drug and that the company was “committed to ensuring that the most vulnerable patients receive treatment first during this period.” The company added that patients should consult a health care professional before undergoing another treatment and that “these medications are not interchangeable.”
“Patient access to these treatments is a top priority for the Food and Drug Administration, and we have provided Sanofi with all the support necessary to ensure that all of our patients’ needs are met,” the Food and Drug Administration said in a statement.
Approximately 1 in 19,000 babies is born with Pompe disease. The disease is named after the Dutch pathologist who discovered it about a century ago.
Patients lack the enzymes that break down complex sugars, so toxic glycogen builds up in their cells. Your muscles may become weaker and your heart may enlarge. They have difficulty breathing and eating. If left untreated, this disease can often lead to death.
Sanofi’s Lumizyme and the second-generation version, Nexviazyme, replace missing enzymes and protect patients’ muscles. Patients typically receive Sanofi’s drug every two weeks.
“This is a lifeline,” said Jenna Yarborough, a rare disease advocate whose two children with Pompe disease are not affected by the drug shortage.
Pompe disease patients rely on Sanofi’s drug, but several other treatments are in clinical trials, including personalized gene therapies from AskBio and Astellas Pharma.
Monique Griffin uses a wheelchair due to Pompe disease, and her blood transfusion was canceled due to a lack of medication.
Monique Griffin
Sanofi has said the drug shortage is the result of problems at its manufacturing facility in Ireland, a problem the company has known about for months, public documents show. The FDA inspected the factory from January 12, 2026 to January 20, 2026, and found violations related to two unrelated drugs. The company began addressing the violations in February, but on June 22, the FDA sent the company a letter warning that it had not yet addressed “fundamental deficiencies” in complying with manufacturing requirements. Sanofi said its response to the FDA’s continued concerns contributed to the supply interruption of Pompe therapy.
There is widespread frustration within the Pompe community that the company did not adequately warn patients about possible supply disruptions. Ryan Colburn, who lives with Pompe and is active in advocacy, said many patients were unaware of Sanofi’s manufacturing problems and had no way of preparing for them. “The lack of proactive transparency and the lack of clear buffers are of great concern for medicines whose lives and well-being depend on access,” Colburn said.
A Sanofi spokesperson responded, “As the situation evolves and the extent of the disruption becomes clear, we have worked collaboratively to inform global and U.S. patient advocacy groups, patients, and clinicians, and have worked to keep these groups and individuals updated through regular communications. We remain committed to continuity of care and transparent, ongoing communication with the Pompe community as we work to stabilize supply.”
Chelsea McGee’s 10-year-old son Logan has been taking Lumizyme every two weeks since he was diagnosed with Pompe disease as an infant. His IV hasn’t been canceled yet, but she’s worried that missing even one appointment could damage his heart. Sanofi’s medication keeps him healthy enough to play soccer.
“It’s important that we stay on his timeline and keep his heart healthy,” she said.
McGee, who lives in Minneapolis, is frustrated by Sanofi’s lack of transparency. She discovered by searching the FDA’s website, not the company, that the FDA was citing drug companies for manufacturing issues.
Griffin, who lives in Orlando, has been taking Lumizyme since 2010, when he was diagnosed with the adult-onset disease. The diagnosis came to light after she was so exhausted that she fell while carrying groceries and suffered a concussion.
She knows what it’s like to live without an IV. She missed several appointments earlier this year due to an insurance mix-up. She likened it to “a really bad flu.” She became extremely fatigued, had difficulty breathing, and began to experience pain in her legs, arms, and back.
Pompe disease is a progressive disease that gets worse over time. Her biggest fear is losing the ability to breathe. She is sleeping with ventilation support.
She works in the theme park industry and would like to attend this week’s conference. Her Lumizyme infusion remains on hold, but she hopes to get through the week of meetings “on caffeine and goodwill.”
CNBC Cures is underwritten by Alexion, AstraZeneca Rare Disaster and BridgeBio.
